The DOI matches its Crossref record; 187 of the 187 references it cites were found in a registry or an index.
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
Open accessAbstract
Growth factors and mitogens use the Ras/Raf/MEK/ERK signaling cascade to transmit signals from their receptors to regulate gene expression and prevent apoptosis. Some components of these pathways are mutated or aberrantly expressed in human cancer (e.g., Ras, B-Raf). Mutations also occur at genes encoding upstream receptors (e.g., EGFR and Flt-3) and chimeric chromosomal translocations (e.g., BCR-ABL) which transmit their signals through these cascades. Even in the absence of obvious genetic mutations, this pathway has been reported to be activated in over 50% of acute myelogenous leukemia and acute lymphocytic leukemia and is also frequently activated in other cancer types (e.g., breast and prostate cancers). Importantly, this increased expression is associated with a poor prognosis. The Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt pathways interact with each other to regulate growth and in some cases tumorigenesis. For example, in some cells, PTEN mutation may contribute to suppression of the Raf/MEK/ERK cascade due to the ability of activated Akt to phosphorylate and inactivate different Rafs. Although both of these pathways are commonly thought to have anti-apoptotic and drug resistance effects on cells, they display different cell lineage specific effects. For example, Raf/MEK/ERK is usually associated with proliferation and drug resistance of hematopoietic cells, while activation of the Raf/MEK/ERK cascade is suppressed in some prostate cancer cell lines which have mutations at PTEN and express high levels of activated Akt. Furthermore the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt pathways also interact with the p53 pathway. Some of these interactions can result in controlling the activity and subcellular localization of Bim, Bak, Bax, Puma and Noxa. Raf/MEK/ERK may promote cell cycle arrest in prostate cells and this may be regulated by p53 as restoration of wild-type p53 in p53 deficient prostate cancer cells results in their enhanced sensitivity to chemotherapeutic drugs and increased expression of Raf/MEK/ERK pathway. Thus in advanced prostate cancer, it may be advantageous to induce Raf/MEK/ERK expression to promote cell cycle arrest, while in hematopoietic cancers it may be beneficial to inhibit Raf/MEK/ERK induced proliferation and drug resistance. Thus the Raf/MEK/ERK pathway has different effects on growth, prevention of apoptosis, cell cycle arrest and induction of drug resistance in cells of various lineages which may be due to the presence of functional p53 and PTEN and the expression of lineage specific factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Zha, J., Harada, H., Yang, E., Jockel, J., & Korsmeyer, S. J. (1996) · Cell · doi:10.1016/s0092-8674(00)81382-3 · Cited by 2,595
Regulation of Cell Death Protease Caspase-9 by Phosphorylation
Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., & Reed, J. C. (1998) · Science · doi:10.1126/science.282.5392.1318 · Cited by 2,481
Mammalian thioredoxin is a direct inhibitor of apoptosis signal‐regulating kinase (ASK) 1
Saitoh, M., Nishitoh, H., Fujii, M., Takeda, K., Tobiume, K., Sawada, Y., Kawabata, M., Miyazono, K., & Ichijo, H. (1998) · The EMBO Journal · doi:10.1093/emboj/17.9.2596 · Cited by 2,377
Ichijo, H., Nishida, E., Irie, K., Dijke, P. T., Saitoh, M., Moriguchi, T., Takagi, M., Matsumoto, K., Miyazono, K., & Gotoh, Y. (1997) · Science · doi:10.1126/science.275.5296.90 · Cited by 2,307
Gewirtz, D. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00307-4 · Cited by 2,240
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019
Cited by
Reactive oxygen species in cancer
Liou, G.-Y., & Storz, P. (2010) · Free Radical Research · doi:10.3109/10715761003667554 · Cited by 3,382
ROS signalling in the biology of cancer
Moloney, J. N., & Cotter, T. G. (2018) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2017.05.023 · Cited by 1,970
Life and death partners: apoptosis, autophagy and the cross-talk between them
Eisenberg-Lerner, A., Bialik, S., Simon, H.-U., & Kimchi, A. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2009.33 · Cited by 1,183
Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy
Santarpia, L., Lippman, S. M., & El-Naggar, A. K. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.645805 · Cited by 1,027
Role of ROS and Nutritional Antioxidants in Human Diseases
Liu, Z., Ren, Z., Zhang, J., Chuang, C.-C., Kandaswamy, E., Zhou, T., & Zuo, L. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00477 · Cited by 860
Svensson, K. J., Christianson, H. C., Wittrup, A., Bourseau-Guilmain, E., Lindqvist, E., Svensson, L. M., Mörgelin, M., & Belting, M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.445403 · Cited by 688
The Potential of Plant Phenolics in Prevention and Therapy of Skin Disorders
Działo, M., Mierziak, J., Korzun, U., Preisner, M., Szopa, J., & Kulma, A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17020160 · Cited by 680
Chen, N., Fang, W., Zhan, J., Hong, S., Tang, Y., Kang, S., Zhang, Y., He, X., Zhou, T., Qin, T., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000500 · Cited by 669
Asati, V., Mahapatra, D. K., & Bharti, S. K. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.01.012 · Cited by 612
Jeong, C.-B., Kang, H.-M., Lee, M.-C., Kim, D.-H., Han, J., Hwang, D.-S., Souissi, S., Lee, S.-J., Shin, K.-H., Park, H. G., et al. (2017) · Scientific Reports · doi:10.1038/srep41323 · Cited by 585
Bernardi, P., Rasola, A., Forte, M., & Lippe, G. (2015) · Physiological Reviews · doi:10.1152/physrev.00001.2015 · Cited by 577
Oxidative stress and dietary phytochemicals: Role in cancer chemoprevention and treatment
Chikara, S., Nagaprashantha, L. D., Singhal, J., Horne, D., Awasthi, S., & Singhal, S. S. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.11.002 · Cited by 559
Steelman, L. S., Chappell, W. H., Abrams, S. L., Kempf, C. R., Long, J., Laidler, P., Mijatovic, S., Maksimovic-Ivanic, D., Stivala, F., Mazzarino, M. C., et al. (2011) · Aging · doi:10.18632/aging.100296 · Cited by 553
Self-citationTaxanes, microtubules and chemoresistant breast cancer
McGrogan, B. T., Gilmartin, B., Carney, D. N., & McCann, A. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.10.004 · Cited by 535
Evaluation of the use of therapeutic peptides for cancer treatment
Marqus, S., Pirogova, E., & Piva, T. J. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0328-x · Cited by 512
Chappell, W. H., Steelman, L. S., Long, J. M., Kempf, R. C., Abrams, S. L., Franklin, R. A., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.240 · Cited by 510
Self-citationBRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
Colombino, M., Capone, M., Lissia, A., Cossu, A., Rubino, C., De Giorgi, V., Massi, D., Fonsatti, E., Staibano, S., Nappi, O., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.2452 · Cited by 471
Targeting cuproplasia and cuproptosis in cancer
Tang, D., Kroemer, G., & Kang, R. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00876-0 · Cited by 443
Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy
Liu, F., Yang, X., Geng, M., & Huang, M. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.01.008 · Cited by 432
The RNA Polymerase I Transcription Machinery: An Emerging Target for the Treatment of Cancer
Drygin, D., Rice, W. G., & Grummt, I. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105844 · Cited by 418
She, Q.-B., Halilovic, E., Ye, Q., Zhen, W., Shirasawa, S., Sasazuki, T., Solit, D. B., & Rosen, N. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.023 · Cited by 400
Phospholipase D: Enzymology, Functionality, and Chemical Modulation
Selvy, P. E., Lavieri, R. R., Lindsley, C. W., & Brown, H. A. (2011) · Chemical Reviews · doi:10.1021/cr200296t · Cited by 389
Serasinghe, M. N., Wieder, S. Y., Renault, T. T., Elkholi, R., Asciolla, J. J., Yao, J. L., Jabado, O., Hoehn, K., Kageyama, Y., Sesaki, H., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.01.003 · Cited by 389
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
Steelman, L. S., Abrams, S. L., Whelan, J., Bertrand, F. E., Ludwig, D. E., Bäsecke, J., Libra, M., Stivala, F., Milella, M., Tafuri, A., et al. (2008) · Leukemia · doi:10.1038/leu.2008.26 · Cited by 385
Self-citationInhibition of Ras for Cancer Treatment: The Search Continues
Baines, A. T., Xu, D., & Der, C. J. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.121 · Cited by 382
PP2A as a master regulator of the cell cycle
Wlodarchak, N., & Xing, Y. (2016) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2016.1143913 · Cited by 371
Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas
Welander, J., Söderkvist, P., & Gimm, O. (2011) · Endocrine-Related Cancer · doi:10.1530/erc-11-0170 · Cited by 355
Reactive oxygen species, nutrition, hypoxia and diseases: Problems solved?
Görlach, A., Dimova, E. Y., Petry, A., Martínez-Ruiz, A., Hernansanz-Agustín, P., Rolo, A. P., Palmeira, C. M., & Kietzmann, T. (2015) · Redox Biology · doi:10.1016/j.redox.2015.08.016 · Cited by 351
What is triple-negative breast cancer?
Irvin, W. J., & Carey, L. A. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.09.034 · Cited by 350
Oncogenic Mutations in GNAQ Occur Early in Uveal Melanoma
Onken, M. D., Worley, L. A., Long, M. D., Duan, S., Council, M. L., Bowcock, A. M., & Harbour, J. W. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-2145 · Cited by 346
Targeting cellular pathways in glioblastoma multiforme
Pearson, J. R. D., & Regad, T. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.40 · Cited by 344
The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer
Shi, Y., Riese, D. J., & Shen, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.574667 · Cited by 336
The post-translational modification, SUMOylation, and cancer (Review)
Han, Z.-J., Feng, Y.-H., Gu, B.-H., Li, Y.-M., & Chen, H. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4280 · Cited by 334
Emerging roles of ECM remodeling processes in cancer
Mohan, V., Das, A., & Sagi, I. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.004 · Cited by 334
Synergy effects of herb extracts: Pharmacokinetics and pharmacodynamic basis
Yang, Y., Zhang, Z., Li, S., Ye, X., Li, X., & He, K. (2014) · Fitoterapia · doi:10.1016/j.fitote.2013.10.010 · Cited by 333
MYC and metabolism on the path to cancer
Hsieh, A. L., Walton, Z. E., Altman, B. J., Stine, Z. E., & Dang, C. V. (2015) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.08.003 · Cited by 332
miRNA-96 Suppresses KRAS and Functions as a Tumor Suppressor Gene in Pancreatic Cancer
Yu, S., Lu, Z., Liu, C., Meng, Y., Ma, Y., Zhao, W., Liu, J., Yu, J., & Chen, J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4531 · Cited by 328
Melatonin: an inhibitor of breast cancer
Hill, S. M., Belancio, V. P., Dauchy, R. T., Xiang, S., Brimer, S., Mao, L., Hauch, A., Lundberg, P. W., Summers, W., Yuan, L., et al. (2015) · Endocrine-Related Cancer · doi:10.1530/erc-15-0030 · Cited by 317
Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma
Dimri, M., & Satyanarayana, A. (2020) · Cancers · doi:10.3390/cancers12020491 · Cited by 311
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia
Park, S., Chapuis, N., Tamburini, J., Bardet, V., Cornillet-Lefebvre, P., Willems, L., Green, A., Mayeux, P., Lacombe, C., & Bouscary, D. (2010) · Haematologica · doi:10.3324/haematol.2009.013797 · Cited by 306
The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC
Li, L., Zhao, G.-D., Shi, Z., Qi, L.-L., Zhou, L.-Y., & Fu, Z.-X. (2016) · Oncology Letters · doi:10.3892/ol.2016.5110 · Cited by 305
Lu, C., Wei, Y., Wang, X., Zhang, Z., Yin, J., Li, W., Chen, L., Lyu, X., Shi, Z., Yan, W., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-1137-5 · Cited by 303
Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming
Mattioli, R., Ilari, A., Colotti, B., Mosca, L., Fazi, F., & Colotti, G. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101205 · Cited by 294
Schwann cells induce cancer cell dispersion and invasion
Deborde, S., Omelchenko, T., Lyubchik, A., Zhou, Y., He, S., McNamara, W. F., Chernichenko, N., Lee, S.-Y., Barajas, F., Chen, C.-H., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci82658 · Cited by 290
Ribosomal Protein S6 Phosphorylation
(2015) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2015.07.006 · Cited by 286
Protein Kinases and Phosphatases in the Control of Cell Fate
Bononi, A., Agnoletto, C., De Marchi, E., Marchi, S., Patergnani, S., Bonora, M., Giorgi, C., Missiroli, S., Poletti, F., Rimessi, A., et al. (2011) · Enzyme Research · doi:10.4061/2011/329098 · Cited by 285
High fat diet induces brain insulin resistance and cognitive impairment in mice
Kothari, V., Luo, Y., Tornabene, T., O'Neill, A. M., Greene, M. W., Geetha, T., & Babu, J. R. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.10.006 · Cited by 282
The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases
Wang, H., Liu, Y., Wang, D., Xu, Y., Dong, R., Yang, Y., Lv, Q., Chen, X., & Zhang, Z. (2019) · Cells · doi:10.3390/cells8121597 · Cited by 279
Phospholipase D Signaling Pathways and Phosphatidic Acid as Therapeutic Targets in Cancer
Bruntz, R. C., Lindsley, C. W., & Brown, H. A. (2014) · Pharmacological Reviews · doi:10.1124/pr.114.009217 · Cited by 276
Mechanism-based cancer therapy: resistance to therapy, therapy for resistance
Ramos, P., & Bentires-Alj, M. (2015) · Oncogene · doi:10.1038/onc.2014.314 · Cited by 272
Pouyan, A., Ghorbanlo, M., Eslami, M., Jahanshahi, M., Ziaei, E., Salami, A., Mokhtari, K., Shahpasand, K., Farahani, N., Meybodi, T. E., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02267-0 · Cited by 271
MALAT1: a potential biomarker in cancer
Li, Z.-X., Zhu, Q.-N., Zhang, H.-B., Hu, Y., Wang, G., & Zhu, Y.-S. (2018) · Cancer Management and Research · doi:10.2147/cmar.s169406 · Cited by 265
MAPK signaling pathways in the regulation of hematopoiesis
Geest, C. R., & Coffer, P. J. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0209097 · Cited by 264
Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
Li, Q., Li, Z., Luo, T., & Shi, H. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00110-2 · Cited by 264
MEK in cancer and cancer therapy
Neuzillet, C., Tijeras-Raballand, A., de Mestier, L., Cros, J., Faivre, S., & Raymond, E. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.10.001 · Cited by 264
Interfering with ROS Metabolism in Cancer Cells: The Potential Role of Quercetin
Gibellini, L., Pinti, M., Nasi, M., De Biasi, S., Roat, E., Bertoncelli, L., & Cossarizza, A. (2010) · Cancers · doi:10.3390/cancers2021288 · Cited by 263
Mechanisms of lncRNA/microRNA interactions in angiogenesis
Zhao, Z., Sun, W., Guo, Z., Zhang, J., Yu, H., & Liu, B. (2020) · Life Sciences · doi:10.1016/j.lfs.2019.116900 · Cited by 262
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
He, Y., Xu, W., Xiao, Y.-T., Huang, H., Gu, D., & Ren, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01042-7 · Cited by 261
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy
Steelman, L. S., Franklin, R. A., Abrams, S. L., Chappell, W., Kempf, C. R., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., Nicoletti, F., et al. (2011) · Leukemia · doi:10.1038/leu.2011.66 · Cited by 261
Self-citationTherapeutic advances of targeting receptor tyrosine kinases in cancer
Tomuleasa, C., Tigu, A.-B., Munteanu, R., Moldovan, C.-S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01899-w · Cited by 260
Irving, J., Matheson, E., Minto, L., Blair, H., Case, M., Halsey, C., Swidenbank, I., Ponthan, F., Kirschner-Schwabe, R., Groeneveld-Krentz, S., et al. (2014) · Blood · doi:10.1182/blood-2014-04-531871 · Cited by 254
Pyakurel, A., Savoia, C., Hess, D., & Scorrano, L. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.02.021 · Cited by 244
Hoeflich, K. P., Merchant, M., Orr, C., Chan, J., Den Otter, D., Berry, L., Kasman, I., Koeppen, H., Rice, K., Yang, N.-Y., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1515 · Cited by 242
Yang, H., Higgins, B., Kolinsky, K., Packman, K., Bradley, W. D., Lee, R. J., Schostack, K., Simcox, M. E., Kopetz, S., Heimbrook, D., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2941 · Cited by 216
“Oncogenic BRAF signaling is implicated in approximately 50% of melanomas, 30–70% of papillary thyroid tumors, 30% of low-grade serous ovarian tumors, and 8–10% of colorectal cancers (CRCs) (2, 5).”
KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
Nagasaka, M., Li, Y., Sukari, A., Ou, S.-H. I., Al-Hallak, M. N., & Azmi, A. S. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101974 · Cited by 185
Oxidative and antioxidative mechanisms in oral cancer and precancer: A review
Choudhari, S. K., Chaudhary, M., Gadbail, A. R., Sharma, A., & Tekade, S. (2014) · Oral Oncology · doi:10.1016/j.oraloncology.2013.09.011 · Cited by 177
Emerging BRAF Mutations in Cancer Progression and Their Possible Effects on Transcriptional Networks
Śmiech, M., Leszczyński, P., Kono, H., Wardell, C., & Taniguchi, H. (2020) · Genes · doi:10.3390/genes11111342 · Cited by 168
Knight, T., & Irving, J. A. E. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00160 · Cited by 164
“This hypothesis is supported by in vitro studies in which activation of the Ras pathway in hematopoietic cells is associated with resistance to glucocorticoids and anthracyclines, key drugs used in ALL therapy (47, 83, 84).”
Metformin Targets Multiple Signaling Pathways in Cancer
Lei, Y., Yi, Y., Liu, Y., Liu, X., Keller, E. T., Qian, C.-N., Zhang, J., & Lu, Y. (2017) · Chinese Journal of Cancer · doi:10.1186/s40880-017-0184-9 · Cited by 152
Wen, Y., Alshikho, M. J., & Herbert, M. R. (2016) · PLOS ONE · doi:10.1371/journal.pone.0153329 · Cited by 150
Current and future perspectives of PD-1/PDL-1 blockade in cancer immunotherapy
Makuku, R., Khalili, N., Razi, S., Keshavarz-Fathi, M., & Rezaei, N. (2021) · Journal of Immunology Research · doi:10.1155/2021/6661406 · Cited by 136
Ocular Adverse Events Associated with Mek Inhibitors
Méndez-Martínez, S., Calvo, P., Ruiz-Moreno, O., Pardiñas Barón, N., Leciñena Bueno, J., Gil Ruiz, M. D. R., & Pablo, L. (2019) · Retina · doi:10.1097/iae.0000000000002451 · Cited by 117
Wu, J., Ivanov, A. I., Fisher, P. B., & Fu, Z. (2016) · eLife · doi:10.7554/elife.10734 · Cited by 117
Raf/MEK/ERK can regulate cellular levels of LC3B and SQSTM1/p62 at expression levels
Kim, J.-H., Hong, S.-K., Wu, P.-K., Richards, A. L., Jackson, W. T., & Park, J.-I. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.08.001 · Cited by 108
Zhang, D., Ma, Q., Wang, Z., Zhang, M., Guo, K., Wang, F., & Wu, E. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-146 · Cited by 106
dos S. Baião, D., da Silva, D. V. T., & Paschoalin, V. M. F. (2020) · Antioxidants · doi:10.3390/antiox9100960 · Cited by 102
Impact of obesity and overweight on DNA stability: Few facts and many hypotheses
Setayesh, T., Nersesyan, A., Mišík, M., Ferk, F., Langie, S., Andrade, V. M., Haslberger, A., & Knasmüller, S. (2018) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2018.07.001 · Cited by 98
Martinelli, E., Troiani, T., D'Aiuto, E., Morgillo, F., Vitagliano, D., Capasso, A., Costantino, S., Ciuffreda, L. P., Merolla, F., Vecchione, L., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28236 · Cited by 92
Switzer, C. H., Glynn, S. A., Ridnour, L. A., Cheng, R. Y.-S., Vitek, M. P., Ambs, S., & Wink, D. A. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.07.001 · Cited by 74
Signaling Pathway Mediating Myeloma Cell Growth and Survival
Hideshima, T., & Anderson, K. C. (2021) · Cancers · doi:10.3390/cancers13020216 · Cited by 70
Quantitative Analysis of ERK2 Interactions with Substrate Proteins
Burkhard, K. A., Chen, F., & Shapiro, P. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.177899 · Cited by 62
Elsum, I. A., Yates, L. L., Pearson, H. B., Phesse, T. J., Long, F., O'Donoghue, R., Ernst, M., Cullinane, C., & Humbert, P. O. (2014) · Oncogene · doi:10.1038/onc.2013.498 · Cited by 60
The MAPK MEK1/2-ERK1/2 Pathway and Its Implication in Hepatocyte Cell Cycle Control
Guégan, J.-P., Frémin, C., & Baffet, G. (2012) · International Journal of Hepatology · doi:10.1155/2012/328372 · Cited by 56
Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
Hao, H.-X., Wang, H., Liu, C., Kovats, S., Velazquez, R., Lu, H., Pant, B., Shirley, M., Meyer, M. J., Pu, M., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0170 · Cited by 53
Ma, Y., Gu, Y., Zhang, Q., Han, Y., Yu, S., Lu, Z., & Chen, J. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0650 · Cited by 55
“dependent on the Raf/MEK/ERK pathway (34, 35).”
Kocik, J., Machula, M., Wisniewska, A., Surmiak, E., Holak, T. A., & Skalniak, L. (2019) · Cancers · doi:10.3390/cancers11071014 · Cited by 46
“This pathway is responsible for many critical functions of the cell response to extracellular stimuli, such as cytokines, growth factors or mitogen binding to their receptors localized in the cell membrane [182,183].”
BackgroundSun, J., Wen, Y., Zhou, Y., Jiang, Y., Chen, Y., Zhang, H., Guan, L., Yao, X., Huang, M., & Bi, H. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0507-z · Cited by 44
A novel prognostic index of hepatocellular carcinoma based on immunogenomic landscape analysis
Xiao, H., Wang, B., Xiong, H., Guan, J., Wang, J., Tan, T., Lin, K., Zou, S., Hu, Z., & Wang, K. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30015 · Cited by 43
Hong, J., Behar, J., Wands, J., Resnick, M., Wang, L. J., DeLellis, R. A., Lambeth, D., & Cao, W. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2774 · Cited by 38
“ERK MAP kinases are key kinases in cell proliferation and cell cycle regulation (46, 47).”
BackgroundDjuzenova, C. S., Fiedler, V., Memmel, S., Katzer, A., Hartmann, S., Krohne, G., Zimmermann, H., Scholz, C.-J., Polat, B., Flentje, M., et al. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.08.013 · Cited by 34
García-Sánchez, D., González-González, A., Alfonso-Fernández, A., Del Dujo-Gutiérrez, M., & Pérez-Campo, F. M. (2023) · World Journal of Stem Cells · doi:10.4252/wjsc.v15.i5.421 · Cited by 32
Chatterjee, S., Rhee, Y., Chung, P.-S., Ge, R.-F., & Ahn, J.-C. (2018) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/j.jphotobiol.2017.12.013 · Cited by 32
Amadeo, F., Trivino Cepeda, K., Littlewood, J., Wilm, B., Taylor, A., & Murray, P. (2021) · Emerging Topics in Life Sciences · doi:10.1042/etls20210013 · Cited by 20
Jensen, H. A., Styskal, L. E., Tasseff, R., Bunaciu, R. P., Congleton, J., Varner, J. D., & Yen, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058621 · Cited by 18
“Phosphorylation at canonical c-Raf activating sites such as S338 and Y340/341 [33,34] cannot be detected in RA-induced WT HL60 cells [35].”
BackgroundInfluential5-Azacytidine engages an IRE1α-EGFR-ERK1/2 signaling pathway that stabilizes the LDL receptor mRNA
Mnasri, N., Mamarbachi, M., Allen, B. G., & Mayer, G. (2018) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2017.11.010 · Cited by 12
Combination Treatment Targeting mTOR and MAPK Pathways Has Synergistic Activity in Multiple Myeloma
Sun, K., Jin, L., Karolová, J., Vorwerk, J., Hailfinger, S., Opalka, B., Zapukhlyak, M., Lenz, G., & Khandanpour, C. (2023) · Cancers · doi:10.3390/cancers15082373 · Cited by 9
Metadata
- Authors
- McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Wong, E. W. T., Chang, F., Lehmann, B., Terrian, D. M., Milella, M., Tafuri, A., Stivala, F., Libra, M., Basecke, J., Evangelisti, C., Martelli, A. M., & Franklin, R. A.
- Venue
- Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Publisher
- Elsevier BV
- Published
- 2007-08
- Volume
- 1773
- Issue
- 8
- Pages
- 1263-1284
- ISSN
- 0167-4889 (ISSN-L)
- OpenAlex
- W2144169031
- Cited by
- 2,284
- References
- 187
- FWCI
- 16.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.